

## **NEWS RELEASE**

## Cardiff Lexington Announces Uplisting to OTCQB Venture Market

2025-05-20

LEXINGTON, KY / ACCESS Newswire / May 20, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that the Company's stock has successfully uplisted and commenced trading on the OTCQB Venture Market (the "OTCQB"), effective Thursday, May 15, 2025. The Company will continue to trade under the ticker symbol "CDIX." This uplisting was achieved following a successful application and approval process to verify that Cardiff Lexington meets OTCQB listing qualifications.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Uplisting to the OTCQB Venture Market represents a significant milestone for our Company and reflects our commitment to transparency, growth, and delivering long-term value to our shareholders. We have made considerable progress expanding our business and putting Cardiff Lexington on track for a record 2025 while also significantly streamlining our capital structure. This achievement enhances our visibility with investors and supports our continued momentum as we move through 2025 and beyond."

The OTCQB, operated by OTC Markets Group and recognized by the U.S. Securities and Exchange Commission (SEC) as a reputable public market for early stage and developing U.S. and internal companies, offers investors essential data to evaluate, value, and trade securities. Cardiff Lexington's inclusion in the OTC Markets Group is expected to support the expansion and diversification of its global shareholder base.

----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and

1

building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management.

Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core

values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a

group of regional primary specialty and ancillary care facilities throughout Florida and Georgia that provide

traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional

pain management, and specialty consultation services.

Cardiff Lexington trades on the OTCQB Venture Market for early stage and developing U.S. and international

companies. Companies are current in their reporting and undergo an annual verification and management

certification process. Investors can find Real-Time quotes and market information for the company on

www.otcmarkets.com.

For more information on Cardiff Lexington Corporation, you may access the company's website at

https://cardifflexington.com/

FORWARD-LOOKING STATEMENT: This news release contains forward-looking statements within the meaning of the

Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events

that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements

of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the

emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of

these uncertainties the forward-looking events referred to in this release might not occur.

Cardiff Lexington Investor Relations

investorsrelations@cardifflexington.com

(800) 628-2100 ext. 705

or

**IMS Investor Relations** 

cardifflexington@imsinvestorrelations.com

(203) 972-9200

**SOURCE: Cardiff Lexington Corporation** 

2

View the original  ${\bf press\ release}$  on ACCESS Newswire

3